“[N]either young age of onset of cannabis use nor high-frequency use of cannabis or the preferred type of cannabis was associated with cannabis-associated psychotic symptoms.”
Region: Switzerland
Forty-seven percent of respondents reported having authorized cannabis-based therapies to their pediatric patients.
Despite the lack of impairment, subjects still tested positive for trace levels of THC — potentially putting them at risk of violating certain traffic safety laws.
Investigators reported “marked improvements” in patients’ symptoms over the course of the trial.
Authors reported that less than one-half of one percent of subjects reported ever having had a cannabis-induced acute psychotic episode during their lifetime.
Researchers observed “no symptoms of impairment” and “no significant impact on driving ability” in study subjects who inhaled CBD-dominant cigarettes.
Researchers identified “an antipsychotic medication sparing effect of CBD-cigarettes as adjunctive therapy in acutely psychotic patients.”
Study participants exhibited a 10 percent “average increase of recalled words 20 minutes after vaping CBD.”